Overview

Neoadjuvant Therapy in Biliary Adenocarcinoma

Status:
Recruiting
Trial end date:
2029-02-04
Target enrollment:
Participant gender:
Summary
Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Jordan Kharofa
Treatments:
Fluorouracil
Gemcitabine